Cervical Cancer Screening
Customize your policy alerts
Sign up for all Blue Cross Blue Shield - North Carolina policy alerts
Know when Blue Cross Blue Shield - North Carolina releases new policies or updates existing guidance.
Monitor payer policy activity
Policy defines coverage criteria, methods, frequencies, and limitations for cervical cancer screening (Pap cytology, high-risk HPV testing, and co-testing) for individuals with a cervix under Blue Cross Blue Shield of North Carolina.
Added CPT code 0502U to Billing/Coding section, effective 10/1/24.
Coverage criteria #1 edited to include immunocompromised; immunocompromised removed from coverage criteria #4 and #6.
Coverage criteria 1a changed from individuals under 30 to individuals of all ages; coverage criteria 1b clarified to 'high-risk'.
Added CPT code 87626 to Billing/Coding section, effective 1/1/2025.
Separated 'When Not Covered' statement into two distinct statements: 'Reimbursement is not allowed for testing for low-risk HPV.' and 'Reimbursement is not allowed for all other indications not discussed above for cervical screening.'
Coverage Criteria and Policy Scope
Covered indications
Covered when criteria below are met (individuals with a cervix):
From reimbursement statements for immunocompromised individuals; details in chunk 5
From chunk 5 and 6
Covered screening and management criteria
Screening recommendations summarized from major guideline sources
USPSTF Grade A; see chunk 22
USPSTF Grade D; see chunk 22
ACS guidance (chunk 27)
ASCCP guidance (chunks 30, 31)
ASCCP and related society guidance summarized in chunk 30
Consensus and guideline updates referenced in policy; see chunk 22 and related guidance
Covered when guideline criteria met
Guideline-based screening recommendations summarized from multiple sources
screening options for average-risk persons aged 21-65
- ages 21-29: Cytology every 3 years is recommended for persons aged 21–29 (co‑testing not recommended under age 30).every 3 years
CDC/USPSTF/ACS references (chunks 44, 22)
- ages 30-65: Options include cytology every 3 years, HPV‑alone every 5 years, or co‑testing every 5 years; primary hrHPV testing is an acceptable alternative and offers greater reassurance of low CIN3+ risk.every 5 years for HPV-alone or co-testing
Society joint guidance and ASCO/CDC references (chunks 36, 47, 44)
ACOG/CDC/ASCCP guidance (chunks 44, 31)
HHS and specialty guidance summarized in chunk 36
ACOG/ASCO guidance (chunks 30, 47)
When Covered (updated summary)
Policy provides coverage when medical criteria and guidelines are met; updates modified multiple coverage statements for clarity including immunocompromised status, age ranges, and test type specifications.
See policy implementation and update log (chunks 61, 62)
Reimbursement is not allowed for cervical cancer screening (including cervical cytology and hr‑HPV testing) for individuals younger than 21 years for any situations not otherwise addressed by the policy. The policy also states screening is not covered for individuals who have had surgical removal of the uterus and cervix and have no history of cervical cancer or precancer.
Screening is not recommended for persons without a cervix following hysterectomy for benign disease; the NCI and USPSTF advise that screening is not helpful in individuals who do not have a cervix. Routine screening is also discouraged for persons younger than 21 years and for persons >65 years who have had adequate prior screening, except when continued surveillance is indicated for specific high‑risk or immunocompromised circumstances.
The American Academy of Family Physicians (Choosing Wisely) specifically recommends: “Don’t perform low‑risk human papillomavirus (HPV) testing.” AAFP explains there is no medical indication for testing low‑risk (non‑oncogenic) HPV types because they are not associated with progression to cervical cancer and detection does not change management.
Operational update: the policy explicitly states that reimbursement is not allowed for testing for low‑risk HPV. This separation clarifies that low‑risk HPV testing is a non‑covered test type regardless of age or other indications.
The policy further clarifies that reimbursement is not allowed for all other indications not discussed above for cervical screening. In other words, any indication for cervical cytology or HPV testing not specifically supported by the coverage criteria should be considered non‑covered unless medical necessity documentation justifies otherwise.
In summary of routine screening exclusions: screening is not covered routinely for individuals younger than 21 years, and routine screening is not covered for individuals >65 years who have had adequate prior screening and are not high‑risk. Persons post‑hysterectomy for benign disease with no history of cervical neoplasia are also excluded from routine screening.
Rationale: major guideline sources (NCI, USPSTF) conclude that the net benefit of routine cervical screening is limited outside recommended age ranges. The NCI notes low benefit and greater harms (false positives, overtreatment) in younger persons, and the USPSTF recommends against screening those younger than 21 and those older than 65 with adequate prior screening because the harms outweigh benefits in these groups.
Applicable service codes are listed in the Billing/Coding section for convenience, but inclusion on that list does not guarantee reimbursement. BCBSNC may request medical records and other documentation to determine medical necessity and may deny reimbursement if documentation does not support coverage under the policy.
Billing and Applicable Codes
| 0502U | Applicable service code |
| 87623 | Applicable service code |
| 87624 | Applicable service code |
| 87625 | Applicable service code |
| 87626 | Applicable service code |
| 88141 | Applicable service code |
| 88142 | Applicable service code |
| 88143 | Applicable service code |
| 88147 | Applicable service code |
| 88148 | Applicable service code |
Provider Requirements, Documentation, and Actions
Prior authorization — none specified
No prior authorization requirements are specified in the portion of this policy.
Prior authorization — none stated
No prior authorization requirements are stated in the provided excerpt of this policy.
Applicable service codes — inclusion not guarantee of reimbursement
Applicable service codes are listed in the Billing/Coding section; inclusion of a code does not guarantee reimbursement and BCBSNC may request medical records to determine medical necessity.
Applicable service codes may be subject to review
The presence of service codes on the policy’s applicable list does not guarantee reimbursement and may be subject to medical necessity review by BCBSNC.
- If medical records are requested, letters of support/explanation are insufficient unless they include all information needed for a medical necessity determination.
Expedited treatment preferred for HSIL/CIN3 risk ≥60%
ASCCP allows expedited treatment (treatment without preceding confirmatory biopsy) as preferred for nonpregnant patients aged ≥25 with HSIL cytology when immediate CIN3+ risk is ≥60%; shared decision-making is recommended.
- Expedited treatment is preferred for HPV-16–positive HSIL cytology and for never/rarely screened patients with HPV-positive HSIL cytology.
- Reflex cytology must be available to enable expedited treatment; if reflex testing from the same specimen is not feasible, proceed directly to colposcopy.
Review member benefit language before applying policy
Review the member’s Benefit Booklet before applying this medical policy; member benefits may vary by benefit design and may affect coverage decisions.
- Apply the terms of this medical policy in the context of the Member's Benefit Booklet.
Perform reflex triage testing from the same specimen for HPV-positive results
For positive primary HPV screening tests, perform reflex triage testing (for example, cytology) from the same laboratory specimen to inform management; if same‑specimen reflex testing is not feasible, collect triage testing at the time of colposcopy.
- Reflex cytology enables risk-based management and supports options such as expedited treatment for HPV16/18 with HSIL cytology.
- If HPV 16/18 testing is positive and reflex testing from the same specimen is not feasible, proceed directly to colposcopy.
Provide medical records when requested for medical necessity review
BCBSNC may request medical records to determine medical necessity; letters of support are not sufficient unless they include all specific information needed for a medical necessity determination.
- When records are requested, provide comprehensive documentation supporting the medical necessity of the service.
Medical records required to support medical necessity
BCBSNC may request medical records to determine medical necessity; letters of support or explanation are insufficient unless they include all specific information needed for the determination.
- Ensure submitted records contain the detailed clinical information required to support coverage under the policy.
Do not perform routine screening for individuals under age 21
Reimbursement is not allowed for routine cervical cancer screening for individuals younger than 21 years of age for situations not addressed in the policy.
- Screening for individuals under 21 is considered not covered/ not medically necessary per policy.
Age-based screening limits — younger than 21 or routine >65 discouraged
Screening outside the recommended age ranges may not be supported; routine screening older than 65 (with adequate prior screening) is discouraged and may not be covered.
- Routine screening over age 65 is not allowed unless the individual is immunocompromised, immunosuppressed, or otherwise high‑risk per policy.
Codes listed do not guarantee reimbursement — documentation may be requested
Inclusion of a code in the Billing/Coding section does not guarantee reimbursement; BCBSNC may request medical records and deny reimbursement if documentation does not support medical necessity.
- Codes listed are examples and are subject to administrative and medical necessity review.
Documentation insufficiency may trigger denial
Presence of a code on the applicable list does not guarantee reimbursement; BCBSNC may request medical records and may deny when documentation is insufficient.
- Ensure documentation fully supports the indication and medical necessity for billed services.
Clinical Background and Evidence Summary
Cervical cancer screening is intended to detect precancerous cervical lesions and invasive cancer through cytology (Pap), HPV testing, and colposcopy. Human papillomavirus (HPV) infection, particularly with oncogenic high‑risk types (notably HPV‑16 and HPV‑18), is causally associated with cervical intraepithelial neoplasia and cervical cancer. FDA‑approved high‑risk HPV nucleic acid tests are validated as adjuncts to cytology or as primary screening methods, and clinician‑collected cervical specimens are the preferred sample; validated at‑home self‑collection devices have also been described.
Definitions and Test Descriptions
OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.